Open AccessEffectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
Author(s) -
Giselda Veronice Hahn,
Jean-Frédéric LeBlanc,
Petra A. Golovics,
Panu Wetwittayakhlang,
Abdulrahman Qatomah,
Anna Wang,
Levon Boodaghians,
Jeremy Liu Chen Kiow,
Maryam Al Ali,
Gary Wild,
Waqqas Afif,
Alain Bitton,
Péter L. Lakatos,
Talat Bessissow
Publication year - 2022
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v28.i33.4823
Subject(s) - medicine , infliximab , ustekinumab , inflammatory bowel disease , ulcerative colitis , adverse effect , adalimumab , vedolizumab , crohn's disease , population , maintenance therapy , retrospective cohort study , gastroenterology , disease , chemotherapy , environmental health
Biologic therapy resulted in a significant positive impact on the management of inflammatory bowel disease (IBD) however data on the efficacy and side effects of these therapies in the elderly is scant.